The Role of Semaphorins in the Pathogenesis of Rheumatoid Arthritis
Abstract
1. Introduction
2. Semaphorins
3. Angiogenesis and Destruction of the Synovial Joint
4. The Possible Use of Semaphorins in RA Treatments
4.1. Class 3 Semaphorins and RA
4.2. Class 4 Semaphorins and RA
4.3. Class 5 Semaphorins and RA
4.4. Class 7 Semaphorins and RA
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Almutairi, K.; Nossent, J.; Preen, D.; Keen, H.; Inderjeeth, C. The global prevalence of rheumatoid arthritis: A meta-analysis based on a systematic review. Rheumatol. Int. 2021, 41, 863–877. [Google Scholar] [CrossRef] [PubMed]
- Szostak, B.; Gorący, A.; Pala, B.; Rosik, J.; Ustianowski, Ł.; Pawlik, A. Latest models for the discovery and development of rheumatoid arthritis drugs. Expert Opin. Drug Discov. 2022, 17, 1261–1278. [Google Scholar] [CrossRef] [PubMed]
- Szostak, B.; Machaj, F.; Rosik, J.; Pawlik, A. Using pharmacogenetics to predict methotrexate response in rheumatoid arthritis patients. Expert Opin. Drug Metab. Toxicol. 2020, 16, 617–626. [Google Scholar] [CrossRef] [PubMed]
- Machaj, F.; Rosik, J.; Szostak, B.; Pawlik, A. The evolution in our understanding of the genetics of rheumatoid arthritis and the impact on novel drug discovery. Expert Opin. Drug Discov. 2020, 15, 85–99. [Google Scholar] [CrossRef] [PubMed]
- Garcia, S. Role of Semaphorins in Immunopathologies and Rheumatic Diseases. Int. J. Mol. Sci. 2019, 20, 374. [Google Scholar] [CrossRef] [PubMed]
- Bullock, J.; Rizvi, S.A.A.; Saleh, A.M.; Ahmed, S.S.; Do, D.P.; Ansari, R.A.; Ahmed, J. Rheumatoid Arthritis: A Brief Overview of the Treatment. Med. Princ. Pract. 2018, 27, 501–507. [Google Scholar] [CrossRef] [PubMed]
- Derksen, V.F.A.M.; Huizinga, T.W.J.; van der Woude, D. The role of autoantibodies in the pathophysiology of rheumatoid arthritis. Semin. Immunopathol. 2017, 39, 437–446. [Google Scholar] [CrossRef] [PubMed]
- Aletaha, D.; Neogi, T.; Silman, A.J.; Funovits, J.; Felson, D.T.; Bingham, C.O.; Birnbaum, N.S.; Burmester, G.R.; Bykerk, V.P.; Cohen, M.D.; et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010, 62, 2569–2581. [Google Scholar] [CrossRef] [PubMed]
- Feldmann, M.; Maini, S.R. Role of cytokines in rheumatoid arthritis: An education in pathophysiology and therapeutics. Immunol. Rev. 2008, 223, 7–19. [Google Scholar] [CrossRef]
- Choy, E. Understanding the dynamics: Pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology 2012, 51 (Suppl. 5), v3–v11. [Google Scholar] [CrossRef]
- Gregersen, P.K.; Silver, J.; Winchester, R.J. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 1987, 30, 1205–1213. [Google Scholar] [CrossRef]
- Harris, E.D. Rheumatoid arthritis. Pathophysiology and implications for therapy. N. Engl. J. Med. 1990, 322, 1277–1289. [Google Scholar] [CrossRef] [PubMed]
- McInnes, I.B.; Schett, G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 2011, 365, 2205–2219. [Google Scholar] [CrossRef]
- Choy, E.H.; Panayi, G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. 2001, 344, 907–916. [Google Scholar] [CrossRef]
- Yan, S.; Kotschenreuther, K.; Deng, S.; Kofler, D.M. Regulatory T cells in rheumatoid arthritis: Functions, development, regulation, and therapeutic potential. Cell. Mol. Life Sci. 2022, 79, 533. [Google Scholar] [CrossRef] [PubMed]
- Alto, L.T.; Terman, J.R. Semaphorins and their Signaling Mechanisms. Methods Mol. Biol. 2017, 1493, 1–25. [Google Scholar] [CrossRef]
- Pasterkamp, R.J.; Giger, R.J. Semaphorin function in neural plasticity and disease. Curr. Opin. Neurobiol. 2009, 19, 263–274. [Google Scholar] [CrossRef]
- Iragavarapu-Charyulu, V.; Wojcikiewicz, E.; Urdaneta, A. Semaphorins in Angiogenesis and Autoimmune Diseases: Therapeutic Targets? Front. Immunol. 2020, 11, 346. [Google Scholar] [CrossRef] [PubMed]
- Nakamura, S.; Nishinaka, A.; Hidaka, Y.; Shimazawa, M.; Thomas, L.; Bakker, R.A.; Hara, H. Efficacy of an Anti-Semaphorin 3A Neutralizing Antibody in a Male Experimental Retinal Vein Occlusion Mouse Model. Investig. Ophthalmol. Vis. Sci. 2022, 63, 14. [Google Scholar] [CrossRef]
- Zippel, N.; Kenny, C.H.; Wu, H.; Garneau, M.; Kroe-Barrett, R.; Gupta, P.; Low, S.; Bakker, R.A.; Thomas, L. Sema3A Antibody BI-X Prevents Cell Permeability and Cytoskeletal Collapse in HRMECs and Increases Tip Cell Density in Mouse Oxygen-Induced Retinopathy. Transl. Vis. Sci. Technol. 2022, 11, 17. [Google Scholar] [CrossRef]
- Xie, J.; Wang, H. Semaphorin 7A as a potential immune regulator and promising therapeutic target in rheumatoid arthritis. Arthritis Res. Ther. 2017, 19, 10. [Google Scholar] [CrossRef] [PubMed]
- Tang, M.W.; Malvar Fernández, B.; Newsom, S.P.; van Buul, J.D.; Radstake, T.R.D.J.; Baeten, D.L.; Tak, P.P.; Reedquist, K.A.; García, S. Class 3 semaphorins modulate the invasive capacity of rheumatoid arthritis fibroblast-like synoviocytes. Rheumatol. (Oxf.) 2018, 57, 909–920. [Google Scholar] [CrossRef] [PubMed]
- Wang, L.; Song, G.; Zheng, Y.; Tan, W.; Pan, J.; Zhao, Y.; Chang, X. Expression of Semaphorin 4A and its potential role in rheumatoid arthritis. Arthritis Res. Ther. 2015, 17, 227. [Google Scholar] [CrossRef] [PubMed]
- Cheng, Q.; Chen, M.; Liu, M.; Chen, X.; Zhu, L.; Xu, J.; Xue, J.; Wu, H.; Du, Y. Semaphorin 5A suppresses ferroptosis through activation of PI3K-AKT-mTOR signaling in rheumatoid arthritis. Cell Death Dis. 2022, 13, 608. [Google Scholar] [CrossRef] [PubMed]
- Kiseleva, E.P.; Rutto, K.V. Semaphorin 3A in the Immune System: Twenty Years of Study. Biochemistry 2022, 87, 640–657. [Google Scholar] [CrossRef] [PubMed]
- Diller, M.; Hasseli, R.; Hülser, M.L.; Aykara, I.; Frommer, K.; Rehart, S.; Müller-Ladner, U.; Neumann, E. Targeting Activated Synovial Fibroblasts in Rheumatoid Arthritis by Peficitinib. Front. Immunol. 2019, 10, 541. [Google Scholar] [CrossRef] [PubMed]
- Catalano, A. The neuroimmune semaphorin-3A reduces inflammation and progression of experimental autoimmune arthritis. J. Immunol. 2010, 185, 6373–6383. [Google Scholar] [CrossRef] [PubMed]
- Avouac, J.; Pezet, S.; Vandebeuque, E.; Orvain, C.; Gonzalez, V.; Marin, G.; Mouterde, G.; Daïen, C.; Allanore, Y. Semaphorins: From Angiogenesis to Inflammation in Rheumatoid Arthritis. Arthritis Rheumatol. 2021, 73, 1579–1588. [Google Scholar] [CrossRef] [PubMed]
- Zheng, J.; Conrad, M. The Metabolic Underpinnings of Ferroptosis. Cell Metab. 2020, 32, 920–937. [Google Scholar] [CrossRef]
- Kumanogoh, A.; Kikutani, H. Immune semaphorins: A new area of semaphorin research. J. Cell Sci. 2003, 116, 3463–3470. [Google Scholar] [CrossRef]
- Sadanandam, A.; Rosenbaugh, E.G.; Singh, S.; Varney, M.; Singh, R.K. Semaphorin 5A promotes angiogenesis by increasing endothelial cell proliferation, migration, and decreasing apoptosis. Microvasc. Res. 2010, 79, 1–9. [Google Scholar] [CrossRef] [PubMed]
- Yoshida, Y.; Ogata, A.; Kang, S.; Ebina, K.; Shi, K.; Nojima, S.; Kimura, T.; Ito, D.; Morimoto, K.; Nishide, M.; et al. Semaphorin 4D Contributes to Rheumatoid Arthritis by Inducing Inflammatory Cytokine Production: Pathogenic and Therapeutic Implications. Arthritis Rheumatol. 2015, 67, 1481–1490. [Google Scholar] [CrossRef] [PubMed]
- Wei, S.T.; Sun, Y.H.; Zong, S.H.; Xiang, Y.B. Serum Levels of IL-6 and TNF-α May Correlate with Activity and Severity of Rheumatoid Arthritis. Med. Sci. Monit. 2015, 21, 4030–4038. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Wu, H.; Deng, R. Angiogenesis as a potential treatment strategy for rheumatoid arthritis. Eur. J. Pharmacol. 2021, 910, 174500. [Google Scholar] [CrossRef] [PubMed]
- Neufeld, G.; Mumblat, Y.; Smolkin, T.; Toledano, S.; Nir-Zvi, I.; Ziv, K.; Kessler, O. The role of the semaphorins in cancer. Cell Adhes. Migr. 2016, 10, 652–674. [Google Scholar] [CrossRef] [PubMed]
- Müller-Ladner, U.; Ospelt, C.; Gay, S.; Distler, O.; Pap, T. Cells of the synovium in rheumatoid arthritis. Synovial fibroblasts. Arthritis Res. Ther. 2007, 9, 223. [Google Scholar] [CrossRef] [PubMed]
- Walsh, D.A.; Pearson, C.I. Angiogenesis in the pathogenesis of inflammatory joint and lung diseases. Arthritis Res. 2001, 3, 147–153. [Google Scholar] [CrossRef]
- Ikeda, M.; Hosoda, Y.; Hirose, S.; Okada, Y.; Ikeda, E. Expression of vascular endothelial growth factor isoforms and their receptors Flt-1, KDR, and neuropilin-1 in synovial tissues of rheumatoid arthritis. J. Pathol. 2000, 191, 426–433. [Google Scholar] [CrossRef]
- MacDonald, I.J.; Liu, S.C.; Su, C.M.; Wang, Y.H.; Tsai, C.H.; Tang, C.H. Implications of Angiogenesis Involvement in Arthritis. Int. J. Mol. Sci. 2018, 19, 2012. [Google Scholar] [CrossRef]
- Jiao, B.; Liu, S.; Tan, X.; Lu, P.; Wang, D.; Xu, H. Class-3 semaphorins: Potent multifunctional modulators for angiogenesis-associated diseases. Biomed. Pharmacother. 2021, 137, 111329. [Google Scholar] [CrossRef]
- Adi, S.D.; Eiza, N.; Bejar, J.; Shefer, H.; Toledano, S.; Kessler, O.; Neufeld, G.; Toubi, E.; Vadasz, Z. Semaphorin 3A Is Effective in Reducing Both Inflammation and Angiogenesis in a Mouse Model of Bronchial Asthma. Front. Immunol. 2019, 10, 550. [Google Scholar] [CrossRef]
- Tatari, N.; Movassagh, H.; Shan, L.; Koussih, L.; Gounni, A.S. Semaphorin 3E Inhibits House Dust Mite-Induced Angiogenesis in a Mouse Model of Allergic Asthma. Am. J. Pathol. 2019, 189, 762–772. [Google Scholar] [CrossRef]
- Lipsky, P.E.; van der Heijde, D.M.; St Clair, E.W.; Furst, D.E.; Breedveld, F.C.; Kalden, J.R.; Smolen, J.S.; Weisman, M.; Emery, P.; Feldmann, M.; et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 2000, 343, 1594–1602. [Google Scholar] [CrossRef] [PubMed]
- Smolen, J.S.; Landewé, R.B.M.; Bergstra, S.A.; Kerschbaumer, A.; Sepriano, A.; Aletaha, D.; Caporali, R.; Edwards, C.J.; Hyrich, K.L.; Pope, J.E.; et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann. Rheum. Dis. 2023, 82, 3–18. [Google Scholar] [CrossRef] [PubMed]
- Machaj, F.; Rosik, J.; Szostak, B.; Malinowski, D.; Safranow, K.; Olędzka, G.; Wiechec, E.; Pawlik, A. The association between CYB5A gene rs1790834 polymorphism and clinical improvement after 6 months of leflunomide treatment in women with rheumatoid arthritis. Clin. Rheumatol. 2023, 42, 2477–2483. [Google Scholar] [CrossRef] [PubMed]
- Qin, Y.; Jin, J.; Zhang, J.; Wang, H.; Liu, L.; Zhang, Y.; Ling, S.; Hu, J.; Li, N.; Wang, J.; et al. A fully human monoclonal antibody targeting Semaphorin 5A alleviates the progression of rheumatoid arthritis. Biomed. Pharmacother. 2023, 168, 115666. [Google Scholar] [CrossRef]
- Gu, C.; Giraudo, E. The role of semaphorins and their receptors in vascular development and cancer. Exp. Cell Res. 2013, 319, 1306–1316. [Google Scholar] [CrossRef]
- Martínez-Ramos, S.; Rafael-Vidal, C.; Malvar-Fernández, B.; Rodriguez-Trillo, A.; Veale, D.; Fearon, U.; Conde, C.; Conde-Aranda, J.; Radstake, T.R.D.J.; Pego-Reigosa, J.M.; et al. HOXA5 is a key regulator of class 3 semaphorins expression in the synovium of rheumatoid arthritis patients. Rheumatology 2023, 62, 2621–2630. [Google Scholar] [CrossRef]
- Suzuki, K.; Kumanogoh, A.; Kikutani, H. Semaphorins and their receptors in immune cell interactions. Nat. Immunol. 2008, 9, 17–23. [Google Scholar] [CrossRef]
- Wang, J.; Liu, C.; Wang, T.; Li, S.; Bai, Y.; Pan, F.; Han, J.; Luo, R.; Wan, X.; Cui, H.; et al. Single-cell communication patterns and their intracellular information flow in synovial fibroblastic osteoarthritis and rheumatoid arthritis. Immunol. Lett. 2023, 263, 1–13. [Google Scholar] [CrossRef]
- Bejar, J.; Kessler, O.; Sabag, A.D.; Sabo, E.; Itzhak, O.B.; Neufeld, G.; Vadasz, Z. Semaphorin3A: A Potential Therapeutic Tool for Lupus Nephritis. Front. Immunol. 2018, 9, 634. [Google Scholar] [CrossRef] [PubMed]
- Eiza, N.; Kessler, O.; Sabag, A.; Neufeld, G.; Jones, E.Y.; Vadasz, Z. Truncated-semaphorin3A is a potential regulatory molecule to restore immune homeostasis in immune-mediated diseases. Front. Pharmacol. 2022, 13, 1085892. [Google Scholar] [CrossRef] [PubMed]
- Vadasz, Z.; Haj, T.; Halasz, K.; Rosner, I.; Slobodin, G.; Attias, D.; Kessel, A.; Kessler, O.; Neufeld, G.; Toubi, E. Semaphorin 3A is a marker for disease activity and a potential immunoregulator in systemic lupus erythematosus. Arthritis Res. Ther. 2012, 14, R146. [Google Scholar] [CrossRef] [PubMed]
- Teng, Y.; Yin, Z.; Li, J.; Li, K.; Li, X.; Zhang, Y. Adenovirus-mediated delivery of Sema3A alleviates rheumatoid arthritis in a serum-transfer induced mouse model. Oncotarget 2017, 8, 66270–66280. [Google Scholar] [CrossRef] [PubMed]
- Prevoo, M.L.; van’t Hof, M.A.; Kuper, H.H.; van Leeuwen, M.A.; van de Putte, L.B.; van Riel, P.L. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995, 38, 44–48. [Google Scholar] [CrossRef] [PubMed]
- Gao, H.; Ma, X.X.; Guo, Q.; Xie, L.F.; Zhong, Y.C.; Zhang, X.W. Expression of circulating Semaphorin3A and its association with inflammation and bone destruction in rheumatoid arthritis. Clin. Rheumatol. 2018, 37, 2073–2080. [Google Scholar] [CrossRef] [PubMed]
- Rimar, D.; Nov, Y.; Rosner, I.; Slobodin, G.; Rozenbaum, M.; Halasz, K.; Haj, T.; Jiries, N.; Kaly, L.; Boulman, N.; et al. Semaphorin 3A: An immunoregulator in systemic sclerosis. Rheumatol. Int. 2015, 35, 1625–1630. [Google Scholar] [CrossRef] [PubMed]
- Takagawa, S.; Nakamura, F.; Kumagai, K.; Nagashima, Y.; Goshima, Y.; Saito, T. Decreased semaphorin3A expression correlates with disease activity and histological features of rheumatoid arthritis. BMC Musculoskelet. Disord. 2013, 14, 40. [Google Scholar] [CrossRef]
- Doron, R.; Merav, L.; Nasrin, E.; Adi, S.D.; Elias, T.; Gleb, S.; Itzhak, R.; Michael, R.; Zahava, V. Low Urine Secretion of Semaphorin3A in Lupus Patients with Proteinuria. Inflammation 2022, 45, 603–609. [Google Scholar] [CrossRef]
- Igea, A.; Carvalheiro, T.; Malvar-Fernández, B.; Martinez-Ramos, S.; Rafael-Vidal, C.; Niemantsverdriet, E.; Varadé, J.; Fernández-Carrera, A.; Jimenez, N.; McGarry, T.; et al. Central Role of Semaphorin 3B in a Serum-Induced Arthritis Model and Reduced Levels in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2022, 74, 972–983. [Google Scholar] [CrossRef]
- Shoda, J.; Tanaka, S.; Etori, K.; Hattori, K.; Kasuya, T.; Ikeda, K.; Maezawa, Y.; Suto, A.; Suzuki, K.; Nakamura, J.; et al. Semaphorin 3G exacerbates joint inflammation through the accumulation and proliferation of macrophages in the synovium. Arthritis Res. Ther. 2022, 24, 134. [Google Scholar] [CrossRef] [PubMed]
- Mohammed, F.F.; Smookler, D.S.; Khokha, R. Metalloproteinases, inflammation, and rheumatoid arthritis. Ann. Rheum. Dis. 2003, 62 (Suppl. 2), ii43–ii47. [Google Scholar] [CrossRef] [PubMed]
- Ha, Y.J.; Han, D.W.; Kim, J.H.; Chung, S.W.; Kang, E.H.; Song, Y.W.; Lee, Y.J. Circulating Semaphorin 4D as a Marker for Predicting Radiographic Progression in Patients with Rheumatoid Arthritis. Dis. Markers 2018, 2018, 2318386. [Google Scholar] [CrossRef] [PubMed]
- Chapoval, S.P. Semaphorin 4A as novel regulator and promising therapeutic target in rheumatoid arthritis. Arthritis Res. Ther. 2015, 17, 313. [Google Scholar] [CrossRef] [PubMed]
- He, R.; Tan, X.; Xiang, J.; Zhu, J.; Jiang, Y.; Liu, W.; Li, Y.; Guo, B.; Xing, Y. Semaphorin 4A as a Potential Biomarker for Diagnosis of Systemic Lupus Erythematosus. Immunol. Investig. 2023, 52, 104–116. [Google Scholar] [CrossRef] [PubMed]
- Avouac, J.; Vandebeuque, E.; Combier, A.; Poiroux, L.; Steelandt, A.; Boisson, M.; Gonzalez, V.; Cauvet, A.; Barnetche, T.; Truchetet, M.E.; et al. Relevance of circulating Semaphorin 4A for rheumatoid arthritis response to treatment. Sci. Rep. 2023, 13, 14626. [Google Scholar] [CrossRef] [PubMed]
- White, I.R.; Kleinstein, S.E.; Praet, C.; Chamberlain, C.; McHale, D.; Maia, J.M.; Xie, P.; Goldstein, D.B.; Urban, T.J.; Shea, P.R. A genome-wide screen for variants influencing certolizumab pegol response in a moderate to severe rheumatoid arthritis population. PLoS ONE 2022, 17, e0261165. [Google Scholar] [CrossRef] [PubMed]
- Pap, T.; Müller-Ladner, U.; Gay, R.E.; Gay, S. Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res. 2000, 2, 361–367. [Google Scholar] [CrossRef] [PubMed]
- Cheng, L.; Wang, Y.; Wu, R.; Ding, T.; Xue, H.; Gao, C.; Li, X.; Wang, C. New Insights From Single-Cell Sequencing Data: Synovial Fibroblasts and Synovial Macrophages in Rheumatoid Arthritis. Front. Immunol. 2021, 12, 709178. [Google Scholar] [CrossRef]
- Xiao, C.; Lv, C.; Sun, S.; Zhao, H.; Ling, H.; Li, M.; Qin, Y.; Zhang, J.; Wang, J.; Yang, X. TSP1 is the essential domain of SEMA5A involved in pannus formation in rheumatoid arthritis. Rheumatology 2021, 60, 5833–5842. [Google Scholar] [CrossRef]
- Gras, C.; Eiz-Vesper, B.; Jaimes, Y.; Immenschuh, S.; Jacobs, R.; Witte, T.; Blasczyk, R.; Figueiredo, C. Secreted semaphorin 5A activates immune effector cells and is a biomarker for rheumatoid arthritis. Arthritis Rheumatol. 2014, 66, 1461–1471. [Google Scholar] [CrossRef]
- Fard, D.; Tamagnone, L. Semaphorins in health and disease. Cytokine Growth Factor Rev. 2021, 57, 55–63. [Google Scholar] [CrossRef] [PubMed]
- Unutmaz, D. RORC2: The master of human Th17 cell programming. Eur. J. Immunol. 2009, 39, 1452–1455. [Google Scholar] [CrossRef] [PubMed]
- Schlaepfer, D.D.; Hunter, T. Integrin signalling and tyrosine phosphorylation: Just the FAKs? Trends Cell Biol. 1998, 8, 151–157. [Google Scholar] [CrossRef] [PubMed]
- Li, X.; Xie, W.; Pan, Q.; Zhang, X.; Zhang, L.; Zhao, N.; Xie, Q.; Ding, J.; Chai, J. Semaphorin 7A interacts with nuclear factor NF-kappa-B p105 via integrin β1 and mediates inflammation. Cell Commun. Signal. 2023, 21, 24. [Google Scholar] [CrossRef]
- Peng, H.; Sun, F.; Jiang, Y.; Guo, Z.; Liu, X.; Zuo, A.; Lu, D. Semaphorin 7a aggravates TGF-β1-induced airway EMT through the FAK/ERK1/2 signaling pathway in asthma. Front. Immunol. 2023, 14, 1167605. [Google Scholar] [CrossRef]
- Song, X.; Meng, J.; Yan, G.; Wang, H.; Li, H.; Lou, D. Semaphorin 7A knockdown improves injury and prevents endothelial-to-mesenchymal transition in ox-LDL-induced HUVECs by regulating β1 integrin expression. Exp. Ther. Med. 2021, 22, 1441. [Google Scholar] [CrossRef] [PubMed]
- Ghofrani, J.; Lucar, O.; Dugan, H.; Reeves, R.K.; Jost, S. Semaphorin 7A modulates cytokine-induced memory-like responses by human natural killer cells. Eur. J. Immunol. 2019, 49, 1153–1166. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Rosik, J.; Kulpa, J.; Szczepanik, M.; Pawlik, A. The Role of Semaphorins in the Pathogenesis of Rheumatoid Arthritis. Cells 2024, 13, 618. https://doi.org/10.3390/cells13070618
Rosik J, Kulpa J, Szczepanik M, Pawlik A. The Role of Semaphorins in the Pathogenesis of Rheumatoid Arthritis. Cells. 2024; 13(7):618. https://doi.org/10.3390/cells13070618
Chicago/Turabian StyleRosik, Jakub, Joanna Kulpa, Marcin Szczepanik, and Andrzej Pawlik. 2024. "The Role of Semaphorins in the Pathogenesis of Rheumatoid Arthritis" Cells 13, no. 7: 618. https://doi.org/10.3390/cells13070618
APA StyleRosik, J., Kulpa, J., Szczepanik, M., & Pawlik, A. (2024). The Role of Semaphorins in the Pathogenesis of Rheumatoid Arthritis. Cells, 13(7), 618. https://doi.org/10.3390/cells13070618